Pharmaceuticals & Biotech

Pipelines, trials, approvals, safety, manufacturing, and next‑gen therapies.

  • 7 Subtopics
  • 9 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

Inside Pharmaceuticals & Biotech

Discovery & Preclinical Targets, assays, animal models, and early safety/tox studies before human trials. Clinical Trials (Phases I–IV) Design, endpoints, enrollment, interim reads, and post‑market surveillance. Approvals, Safety & REMS FDA/EMA decisions, boxed warnings, pharmacovigilance, and label changes. Generics & Biosimilars Access, interchangeability, litigation, and pricing dynamics for follow‑ons. Vaccines & Immunization Platforms (mRNA, viral vector), boosters, schedules, and cold‑chain supply. Cell & Gene Therapies CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up. Manufacturing & Supply APIs, sterile fill‑finish, shortages, and quality systems across the supply chain.

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Pharmaceuticals & Biotech


wbng.com > video > 10/12/2026 > southern-tier-aids-program-cocktails-cause

Southern Tier Aids Program: Cocktails for a Cause

4+ hour, 31+ min ago   (38+ words) WBNG Southern Tier Aids Program: Cocktails for a Cause A few rain chances this week with cooler temps on the way Black bears open season with 5-2 win over Watertown...


mycarrollcountynews.com > online_features > press_releases > article_a69c8c39-791d-5128-bb74-45971b93e7a0.html

Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity

2+ hour, 2+ min ago   (677+ words) Two oral presentations at AHA Hypertension 2026 demonstrate the pronounced efficacy of aprocitentan in two groups of patients with notoriously difficult to control hypertension from the PRECISION study: patients with obesity and patients across the cardiovascular-kidney-metabolic (CKM) continuum. In both groups…...


tradingview.com > news > tradingview:fec022b8596fc:0-weekly-recap-abogen-mrna-t-cell-engager-investment-and-rhapsido-approval

Weekly Recap: Abogen mRNA T‑cell engager investment and Rhapsido approval

2+ hour, 2+ min ago   (153+ words) TradingView Weekly Recap: Abogen mRNA T‑cell engager investment and Rhapsido approval Novartis AG (SIX:NOVN) is boosting its immunology and neurology pipeline—investing $575M in Abogen for ABO2203 mRNA T‑cell engagers with up to $7.8B milestones, winning FDA approval for Rhapsido…...


petra.gov.jo > en > news > jfda-highlights-jordans-pioneer-role-in-regional-pharmaceutical-studies

JFDA highlights Jordan's pioneer role in regional pharmaceutical studies

11+ hour, 48+ min ago   (313+ words) وكالة الانباء الاردنية JFDA highlights Jordan's pioneer role in regional pharmaceutical studies Amman, Oct. 11 (Petra) -- Director General of the Jordan Food and Drug Administration (JFDA) Rana Obeidat affirmed Sunday that Jordan remains a regional pioneer in pharmaceutical studies, backed by…...


medicaleconomics.com > view > fda-approves-eli-lilly-s-weight-loss-pill-judge-revokes-citizenship-over-stolen-medical-secrets-for-china-new-covid-19-cicada-variant-spreads-to-25-states-morning-medical-update

FDA approves Eli Lilly’s weight-loss pill; Judge revokes citizenship over stolen medical secrets for China; new COVID-19 ‘Cicada’ variant spreads to 25 states – Morning Medical Update

33+ min ago   (154+ words) The top news stories in medicine today. The once-daily oral drug, orforglipron, will be available for $149 a month starting April 6 — on par with Novo Nordisk's oral Wegovy. The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's once-daily weight-loss…...


crisprmedicinenews.com > news > cmn-webinar-expert-discussion-rethinking-cell-gene-therapy-safety

CMN Webinar - Expert Discussion: Rethinking Cell & Gene Therapy Safety

37+ min ago   (331+ words) CRISPR Medicine News CMN Webinar - Expert Discussion: Rethinking Cell & Gene Therapy Safety Many cell and gene therapy (CGT) developers use gene editing techniques to generate the therapy or produce the desired therapeutic outcome. However, standard quality control and analytical methods…...


aop.org.uk > ot > features > 10/12/2026 > innovation-in-action-how-new-glp1s-new-treatments-and-ai-are-changing-ophthalmology

Innovation in action: how new GLP-1s, new treatments and AI are changing ophthalmology

53+ min ago   (410+ words) Three Moorfields Private consultants reflect on three changing areas of eye care Advertorial content is paid for and produced by a sponsor, and is reviewed and edited by the OT team before publication. Advances in ophthalmology are creating new opportunities…...


koreabiomed.com > news > articleView.html

[Interview] Covid-19 poses greater threat than flu, yet fewer Koreans get vaccinated: expert

4+ hour, 33+ min ago   (1186+ words) Covid-19 may no longer be a pandemic, but it continues to pose a greater risk of severe illness and death than influenza, particularly among older adults and immunocompromised patients, according to a Korean infectious disease specialist. Yet vaccination rates among…...


grafa.com > en > news > australia > acrux-secures-fda-phase-3-pathway-approval

Acrux secures FDA Phase 3 pathway approval

3+ hour, 29+ min ago   (225+ words) Assets related to this article Acrux (ASX:ACR) has secured a confirmed Phase 3 regulatory pathway from the U.S. Food and Drug Administration for its female testosterone metered-dose transdermal spray targeting hypoactive sexual desire disorder. The agreement follows an end-of-Phase 2 meeting with…...


actionnewsjax.com > news > trending > retatrutide-new-drug-shows-weight-loss-promise > 2M7FYPWPOVHZPAB4K6E6J7GH34

Retatrutide: New drug shows weight loss promise

52+ min ago   (324+ words) Another drug may soon hit the market to help battle obesity. Retatrutide, made by Eli Lilly, is a GLP-1 that, according to a new trial published in The Lancet this week, helped people with Type 2 diabetes lose up to 60 pounds…...